Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

by Zacks Equity Research

Bio-Rad (BIO) seeing solid revenue growth in geographies like Americas and Asia Pacific buoys optimism.

Zacks Equity Research

HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?

by Zacks Equity Research

DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 1st

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 26th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Zacks Equity Research

Integer Holdings' (ITGR) 2019 View Strong Despite Rivalry

by Zacks Equity Research

Integer Holdings (ITGR) holds a solid position in the MedTech space but is still exposed to competition.

Zacks Equity Research

Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong

by Zacks Equity Research

Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.

Zacks Equity Research

Integer (ITGR) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 13.04% and 1.74%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Integer (ITGR) Q4 Earnings Expected to Decline

by Zacks Equity Research

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is Integer Holdings (ITGR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ITGR) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why Investors Should Hold Patterson Companies Stock

by Zacks Equity Research

Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.

Zacks Equity Research

Here's Why Investors Should Hold McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.

Zacks Equity Research

Omnicell (OMCL) Rides on Innovation Despite Cost Concerns

by Zacks Equity Research

Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.

Zacks Equity Research

Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.

Zacks Equity Research

LMNX or PACB: Which is a Better MedTech Investment Pick?

by Zacks Equity Research

Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.

Zacks Equity Research

LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite

by Zacks Equity Research

LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.

Zacks Equity Research

Here's Why You Should Add CVS Health to Your Portfolio Now

by Zacks Equity Research

CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.

Zacks Equity Research

Solid Global Business Aids NuVasive Amid Pricing Pressure

by Zacks Equity Research

Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.

Zacks Equity Research

Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

by Zacks Equity Research

Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

by Zacks Equity Research

A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.

Zacks Equity Research

Cardiovascular Systems Gets Approvals in Japan, Widens Suite

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.

Zacks Equity Research

Here's Why You Should Invest in Wright Medical (WMGI) Now

by Zacks Equity Research

A bullish outlook and a wide array of products make Wright Medical (WMGI) a promising investment pick.

Zacks Equity Research

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.

Zacks Equity Research

Walgreens Counts on International Progress, Strategic Deals

by Zacks Equity Research

We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.

Zacks Equity Research

Cardiovascular Systems Treats First Patient With Teleport

by Zacks Equity Research

Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.

Zacks Equity Research

Here's Why You Should Invest in Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Hill-Rom's (HRC) M&A pipeline continues to be strong.